Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients.
Sign Up to like & getrecommendations! Published in 2021 at "Infectious diseases and therapy"
DOI: 10.1007/s40121-021-00542-3
Abstract: Introduction The aim of the present study was to assess the safety profile and outcomes of a ceftazidime-avibactam (CAZ-AVI)-based regimen and compare them with those of a tigecycline (TGC)-based regimen in intensive care unit (ICU)… read more here.
Keywords: caz avi; treatment; group; critically ill ... See more keywords
MIC Profiling of Ceftazidime-Avibactam against two Carbapenemase producing Klebsiella pneumoniae Isolates.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of global antimicrobial resistance"
DOI: 10.1016/j.jgar.2020.10.014
Abstract: OBJECTIVE To correlate results of a modified susceptibility testing method to outcomes of ceftazidime-avibactam (CAZ/AVI) therapy. METHODS Two bloodstreamK. pneumoniae isolates (CAZ/AVI susceptible) from an abdominal source were recovered from 2 unrelated patients. Both patients… read more here.
Keywords: ceftazidime avibactam; caz avi; mic profiling; caz ... See more keywords
IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AGAINST GRAM-NEGATIVE STRAINS IN COLOMBIA 2014-2018.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of global antimicrobial resistance"
DOI: 10.1016/j.jgar.2022.02.018
Abstract: BACKGROUND Ceftazidime/avibactam (CAZ/AVI) has shown in vitro activity against multidrug-resistant (MDR) Gram-negative bacteria, especially Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa. However, in vitro activity of CAZ/AVI against Gram-negative bacteria in Colombian hospitals is still unknown. The… read more here.
Keywords: gram negative; vitro activity; caz avi; activity ... See more keywords
Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-14817-z
Abstract: Carbapenem-resistant Enterobacterales (CRE), particularly carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-resistant Escherichia coli (CREC), are significant pathogens causing healthcare-associated infections. This retrospective study assesses the effectiveness of ceftazidime-avibactam (CAZ/AVI) in achieving perianal swab (PAS) negativity compared… read more here.
Keywords: caz avi; carbapenem resistant; pas negativity; negativity ... See more keywords
Pharmacokinetic parameters of CAZ–AVI in the normal lung and in models of pneumonia: lessons for treatment optimization in critical care
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2024.2308977
Abstract: Abstract The spread of multidrug-resistant Gram-negative bacterial infections is a significant issue for worldwide public health. Gram-negative organisms regularly develop resistance to antibiotics, especially to β-lactam antimicrobials, which can drastically restrict the number of therapies.… read more here.
Keywords: caz avi; gram negative; lung; models pneumonia ... See more keywords
Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial
Sign Up to like & getrecommendations! Published in 2025 at "Journal of the Pediatric Infectious Diseases Society"
DOI: 10.1093/jpids/piaf028
Abstract: Abstract Background This phase 2a study evaluated pharmacokinetics and safety of ceftazidime-avibactam (CAZ/AVI; combination dosed as fixed 4:1 ratio) in neonates and young infants with suspected/confirmed infections due to Gram-negative pathogens requiring intravenous antibiotics. Methods… read more here.
Keywords: caz avi; young infants; part; neonates young ... See more keywords
1313. MIC Profiling of Ceftazidime-Avibactam (CAZ/AVI) Against Two Carbapenemase producing Klebsiella pneumoniae Isolates
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1495
Abstract: Carbapenemases confer resistance against a broad range of beta-lactams with a prevalence of 40-60% among CRE (carbapenem-resistant Enterobacteriaceae). CAZ-AVI is commonly used to treat infections due to CPE (carbapenemase-producing Enterobacteriaceae), typically guided by susceptibility testing… read more here.
Keywords: carbapenemase producing; caz avi; mic profiling; caz ... See more keywords
1580. In Vitro Activity of Ceftazidime-Avibactam Against Enterobacterales and Pseudomonas aeruginosa Collected in Latin America as part of the ATLAS Global Surveillance Program, 2017-2019
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1760
Abstract: Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination with in vitro activity against Enterobacterales (Ent) and Pseudomonas aeruginosa (Psa) carrying Class A, C and some Class D β-lactamases. We examined the in vitro activity of… read more here.
Keywords: caz avi; pfizer; employee; vitro activity ... See more keywords
1604. Cost-Effectiveness of Ceftazidime-Avibactam for Patients with Hospital-Acquired Pneumonia Caused by Multi-Drug Resistant Enterobacteriaceae or Pseudomonas in China
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1784
Abstract: To estimate the cost-effectiveness of ceftazidime-avibactam (CAZ-AVI) for the treatment of hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) caused by multi-drug resistant enterobacteriaceae (MDRE) or MDR pseudomonas aeruginosa (MDRPA) in China. A previously published patient-level… read more here.
Keywords: caz avi; effectiveness ceftazidime; pfizer; cost ... See more keywords
Comparative in vitro Activities of Ceftazidime–Avibactam and Ceftolozane-tazobactam Against Characterized β-Lactamase-producing Pseudomonas aeruginosa
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.897
Abstract: Abstract Background Ceftazidime-avibactam (CAZ-AVI) and ceftolozane-tazobactam (TOL-TAZ) are cephalosporin/β-lactamase inhibitor combinations recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). Both agents are reported to have antibacterial activity… read more here.
Keywords: lactamase; caz avi; tol taz; lactamase producing ... See more keywords
Ceftazidime-avibactam and Meropenem Double Disk Diffusion Test for Identifying Carbapanem-Resistant Enterobacteriaceae and Distinguishing Between Serine and Metallo-β-Lactamase Producing Organisms
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.923
Abstract: Abstract Background Early detection of carbapenem-resistant Enterobacteriaceae(CRE) is crucial for selection of effective treatment. While KPC is the most prevalent carbapenemase in the US, phenotypic screening methods, such as the carbapenemase inactivation method (CIM) and… read more here.
Keywords: caz avi; producing organisms; disk; mer ... See more keywords